13G Filing: Park West Asset Management and PLx Pharma Inc. (PLXP)

Page 3 of 12

Page 3 of 12 – SEC Filing

CUSIP No.  72942A107
(1) Names of Reporting Persons
Park
West Investors Master Fund, Limited
(2) Check the Appropriate Box if a Member of a Group (See Instructions)   (a) [    ]
  (b) [    ]
(3) SEC Use Only
(4) Citizenship or Place of Organization
Cayman
Islands
Number of Shares Beneficially Owned by Each Reporting Person With:
(5) Sole Voting Power: 953,465*
(6) Shared Voting Power: 0
(7) Sole Dispositive Power: 953,465*
(8) Shared Dispositive Power: 0
   
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
953,465*
(10) Check if the Aggregate Amount  in Row (9)
Excludes Certain Shares (See Instructions):
[    ]
(11) Percent of Class Represented by Amount in Row (9)
11.0%*
(12) Type of Reporting Person (See Instructions):
IA

* Beneficial ownership percentage is based
upon 8,683,915 shares of Common Stock issued and outstanding immediately after the consummation of the Company’s public
offering of Common Stock, as reported by the Company in its prospectus supplement dated June 9, 2017 (File No. 333-204830), filed
with the Securities and Exchange Commission on June 12, 2017. As of June 9, 2017, PWIMF held 953,465 shares of Common Stock and,
subject to the limitation described below, warrants to purchase up to 902,528 shares of Common Stock. The warrants are not exercisable
until December 15, 2017, expire on June 14, 2027, and contain a provision prohibiting exercise to the extent that the holder,
together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately
after giving effect to such exercise (subject to decrease upon prior written notice to the Company).  For purposes
of Reg. Section 240.13d-3, PWIMF may be deemed to beneficially own 953,465 shares of Common Stock, and no shares of Common Stock
underlying the warrants, for an aggregate beneficial ownership percentage of approximately 11.0% of the shares of Common Stock
deemed issued and outstanding as of June 9, 2017.

Follow Plx Pharma Inc. (NASDAQ:PLXP)

Page 3 of 12